CLEU15006 / S1318 / Kristen O'DwyerResearch Question:
What are the good and/or bad effects of adding the drug blinatumomab to different
doses of standard combinations of chemotherapy drugs?
Can standard therapy drugs can be given at lower doses (when given with blinatumomab)
in order to reduce overall side effects and be effective in treating ALL?
Basic Study Information
Purpose:Location: Cancer Center
This phase II trial studies the side effects and how well blinatumomab and combination
chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients
with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such
as blinatumomab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such
as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Dasatinib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab
with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02143414?term=S1318&rank=1
Study Reference #: CLEU-15006
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Learn More About These Conditions
More information about Acute lymphoblastic leukemia [ALL]
Trial Not Found
The study you are looking for is not active at this time.
Return to Search